Aztréonam : interactions médicamenteuses
Aztréonam (Azactam, Cayston), antibiotique, présente 46 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 0 de niveau majeur, 46 de niveau modéré, 0 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.
Interactions d'après la notice
Interactions modérées (46)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)
Vérifiez Aztréonam avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.